CHAPTER 2.2 76 37. Paolillo S, Scardovi AB, Campodonico J. Role of comorbidities in heart failure prognosis Part I: Anaemia, iron deficiency, diabetes, atrial fibrillation. Eur J Prev Cardiol 2020;27:27–34. doi:10.1177/2047487320960288. 38. Bertero E, Canepa M, Maack C, Ameri P. Linking Heart Failure to Cancer. Circulation 2018;138:735– 742. doi:10.1161/CIRCULATIONAHA.118.033603. 39. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research. Adaptive Designs for Clinical Trials of Drugs and Biologics. Guidance for Industry. Silver Spring, MD: Center for Drug Evaluation and Research; 2019. 40. Fiuzat M, Hamo CE, Butler J, Abraham WT, DeFilippis EM, Fonarow GC, et al. Optimal Background Pharmacological Therapy for Heart Failure Patients in Clinical Trials. Journal of the American College of Cardiology 2022;79:504–510. doi:10.1016/j.jacc.2021.11.033. 41. Kim JH, Ta CN, Liu C, Sung C, Butler AM, Stewart LA, et al. Towards clinical data-driven eligibility criteria optimization for interventional COVID-19 clinical trials. J Am Med Inform Assoc 2021;28:14– 22. doi:10.1093/jamia/ocaa276.
RkJQdWJsaXNoZXIy MjY0ODMw